Monitoring the therapeutic efficacy of BD-218 in COVID-19 patients

Aimmune Therapeutics
Role

Chief Investigator

Description

Our goal is to accelerate the development of SARS-CoV-2 neutralising antibody, BD-218, towards a first-in-human Phase I toxicity and dose-escalation trial at Royal Prince Alfred Hospital, NSW and The Alfred Hospital, Victoria in mid-2020.

Date

01 Jan 2021 - 31 Dec 2021

Project Type

GRANT

Keywords

N/A

Funding Body

Aimmune Therapeutics

Amount

50000

Project Team

N/A